Pfizer Prevails at Third Circuit in Class Suit Over Alzheimer's Drug

, New Jersey Law Journal

   | 0 Comments

The Third Circuit has upheld dismissal of a New Jersey-based securities class action against a Pfizer subsidiary that allegedly lied about the success of an Alzheimer's Disease treatment under development.

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article# 1202658692179

Thank you!

This article's comments will be reviewed.